- Home
- VSTM vs SVRA Comparison
VSTM vs SVRA Comparison
Compare VSTM & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- SVRA
- Stock Information
- Founded
- VSTM 2010
- SVRA 2007
- Country
- VSTM United States
- SVRA United States
- Employees
- VSTM N/A
- SVRA N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- VSTM Health Care
- SVRA Health Care
- Exchange
- VSTM Nasdaq
- SVRA Nasdaq
- Market Cap
- VSTM 581.6M
- SVRA 527.2M
- IPO Year
- VSTM 2012
- SVRA N/A
- Fundamental
- Price
- VSTM $10.71
- SVRA $5.35
- Analyst Decision
- VSTM Strong Buy
- SVRA Buy
- Analyst Count
- VSTM 9
- SVRA 8
- Target Price
- VSTM $13.38
- SVRA $6.88
- AVG Volume (30 Days)
- VSTM 2.8M
- SVRA 2.1M
- Earning Date
- VSTM 11-04-2025
- SVRA 11-12-2025
- Dividend Yield
- VSTM N/A
- SVRA N/A
- EPS Growth
- VSTM N/A
- SVRA N/A
- EPS
- VSTM N/A
- SVRA N/A
- Revenue
- VSTM $13,379,000.00
- SVRA N/A
- Revenue This Year
- VSTM $88.60
- SVRA N/A
- Revenue Next Year
- VSTM $416.99
- SVRA N/A
- P/E Ratio
- VSTM N/A
- SVRA N/A
- Revenue Growth
- VSTM 33.79
- SVRA N/A
- 52 Week Low
- VSTM $3.46
- SVRA $1.89
- 52 Week High
- VSTM $11.25
- SVRA $5.49
- Technical
- Relative Strength Index (RSI)
- VSTM 65.97
- SVRA 76.92
- Support Level
- VSTM $7.29
- SVRA $4.59
- Resistance Level
- VSTM $10.45
- SVRA $4.38
- Average True Range (ATR)
- VSTM 0.68
- SVRA 0.29
- MACD
- VSTM 0.23
- SVRA 0.10
- Stochastic Oscillator
- VSTM 93.53
- SVRA 91.38
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.